Mavacamten in non-obstructive Hypertrophic Cardiomyopathy (HCM)
Summary
The purpose of this study is to test that treatment with oral mavacamten improves health status (symptoms and physical limitations) and increases exercise capacity in participants with Non-obstructive Hypertrophic Cardiomyopathy(nHCM) who are having symptoms and have diminished physical function and exercise capacity.
Eligibility
Eligible gender: Male, Female
Eligible ages: 18 to 100
Inclusion criteria:
You may be eligible to participate in this trial if you are:
- 18+ years old
- Have been diagnosed with Non-obstructive Hypertrophic Cardiomyopathy(nHCM)
Doctors will also evaluate other criteria to make sure you qualify for the study.
Exclusion criteria:
You may not be eligible to participate in this trial if you are:
- Female who is breastfeeding or pregnant
- Heart transplant recipient or listed for heart transplant
- Body weight < 45 kg
Doctors will also evaluate other criteria to make sure your child qualify for the study.
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Dr. Robert Miller at Robert.Miller@albertahealthservices.ca or 403.220.8191
Principal investigator:
Robert Miller
Clinical trial:
Yes
REB-ID:
REB23-0322